What is a stock summary page? Click here for an overview.
Business Description
aTyr Pharma Inc
NAICS : 325414
SIC : 2836
ISIN : US0021201035
Description
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.43 | |||||
| Equity-to-Asset | 0.72 | |||||
| Debt-to-Equity | 0.19 | |||||
| Debt-to-EBITDA | -0.2 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Altman Z-Score | -2.86 | |||||
| Beneish M-Score | -2.73 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 19.5 | |||||
| 3-Year EPS without NRI Growth Rate | 21.4 | |||||
| 3-Year FCF Growth Rate | 18.8 | |||||
| 3-Year Book Growth Rate | -40.4 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 838.82 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 15.31 | |||||
| 9-Day RSI | 29.62 | |||||
| 14-Day RSI | 36.84 | |||||
| 3-1 Month Momentum % | 9.25 | |||||
| 6-1 Month Momentum % | 124.72 | |||||
| 12-1 Month Momentum % | 102.82 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.48 | |||||
| Quick Ratio | 5.48 | |||||
| Cash Ratio | 4.82 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -44.6 | |||||
| Shareholder Yield % | -14.02 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -28899.57 | |||||
| Net Margin % | -27243.83 | |||||
| FCF Margin % | -29440 | |||||
| ROE % | -81.65 | |||||
| ROA % | -60.59 | |||||
| ROIC % | -395.25 | |||||
| 3-Year ROIIC % | -257.2 | |||||
| ROC (Joel Greenblatt) % | -532.62 | |||||
| ROCE % | -74.64 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 721.17 | |||||
| PB Ratio | 3.47 | |||||
| Price-to-Tangible-Book | 3.47 | |||||
| EV-to-EBIT | -3.08 | |||||
| EV-to-Forward-EBIT | -2.8 | |||||
| EV-to-EBITDA | -3.15 | |||||
| EV-to-Forward-EBITDA | -2.8 | |||||
| EV-to-Revenue | 888.85 | |||||
| EV-to-Forward-Revenue | 41.81 | |||||
| EV-to-FCF | -3.17 | |||||
| Price-to-Net-Current-Asset-Value | 4.36 | |||||
| Price-to-Net-Cash | 5.33 | |||||
| Earnings Yield (Greenblatt) % | -32.47 | |||||
| FCF Yield % | -27.03 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ATYR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
aTyr Pharma Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.235 | ||
| EPS (TTM) ($) | -0.87 | ||
| Beta | 0.84 | ||
| 3-Year Sharpe Ratio | 0.1 | ||
| 3-Year Sortino Ratio | 0.18 | ||
| Volatility % | 91.48 | ||
| 14-Day RSI | 36.84 | ||
| 14-Day ATR ($) | 0.302044 | ||
| 20-Day SMA ($) | 3.46675 | ||
| 12-1 Month Momentum % | 102.82 | ||
| 52-Week Range ($) | 1.42 - 4.66 | ||
| Shares Outstanding (Mil) | 88.86 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
aTyr Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
aTyr Pharma Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
aTyr Pharma Inc Frequently Asked Questions
What is aTyr Pharma Inc(ATYR)'s stock price today?
The current price of ATYR is $2.88. The 52 week high of ATYR is $4.66 and 52 week low is $1.42.
When is next earnings date of aTyr Pharma Inc(ATYR)?
The next earnings date of aTyr Pharma Inc(ATYR) is 2025-05-02 Est..
Does aTyr Pharma Inc(ATYR) pay dividends? If so, how much?
aTyr Pharma Inc(ATYR) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers